Header Logo

Connection

Matthew Parker to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Matthew Parker has written about Cost-Benefit Analysis.
Matthew Parker
Connection Strength
0.025
Cost-Benefit Analysis
  1. Kohn CG, Parker MW, Limone BL, Coleman CI. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris. Am J Cardiol. 2014 Apr 15; 113(8):1306-11.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.